Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 1/2 1

Status

Terminated 5Completed 5Unknown 2Withdrawn 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Thoracic 1Head & Neck 1

Conditions

Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 741Cisplatin 688Gemcitabine 641Bevacizumab 616Carboplatin 605Paclitaxel 601Docetaxel 565Radiotherapy 536Fluorouracil 405Oxaliplatin 387Rituximab 369Doxorubicin 361Capecitabine 342Filgrastim 333Etoposide 330Dexamethasone 312Irinotecan 309pembrolizumab 282Leucovorin 274Cetuximab 268Cytarabine 242Erlotinib Hydrochloride 231Nivolumab 228Prednisone 227Trastuzumab 225Vincristine 221Bortezomib 221Methotrexate 207Pemetrexed 199fludarabine phosphate 195

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Completed × HM781-36B × Clear all
NCT03292250 2022-03-29

Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]

Seoul National University Hospital

Phase 2 Completed
180 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02659514 2022-03-11

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Spectrum Pharmaceuticals, Inc

Phase 2 Completed
67 enrolled 16 charts
Breast

Breast Neoplasms

NCT02418689 2022-01-20

Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens

Hanmi Pharmaceutical Company Limited

Phase 2 Completed
106 enrolled
Breast

Breast Neoplasms

NCT02544997 2020-07-07

A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway

Samsung Medical Center

Phase 2 Completed
5 enrolled
Breast

Breast Neoplasms

NCT02979821 2018-05-24

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

Korean Association for the Study of Targeted Therapy

Phase 2 Completed
6 enrolled
Thoracic

Adenocarcinoma of Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡